ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
The evolving relationship between sponsors and contract research organisations
In this article, Jeffrey James, EVP Alliance Management, offers his insights on what it takes to be a trusted partner to sponsors in the clinical development industry.
Measuring the cost-effectiveness of vaccines targeting infectious diseases
Using real-world evidence, this article shows how vaccines benefit healthcare systems through cost-effectiveness models.
Drug development practices to improve public health policy
In this article, Dr Andrew Garrett, Executive Vice President of Scientific Operations, explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between NPIs and PIs and identify where standards can be improved and enforced.
Responsive strategies in vaccine development
This article discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
Mainstreaming cell and gene therapy – Realizing its potential
This article looks at the CGT landscape, the challenges biopharma companies face in running clinical trials and tips on how to surmount those obstacles.
Language: A key component of diverse and inclusive trials
ICON Language Services Director Patrick Majewski shares the importance of and key considerations in clinical trial translations.
The role of digital health technology tools in supporting medical adherence
This article outlines the role of digital health technology tools in supporting medical adherence.
Voice enabling participant diary collection powered by AI on AWS – Part 2
Read how our partnership with AWS has allowed us to integrate voice enabled diary collection into trials and how it contributes to a better participant experience.
Inclusive approaches to diversity and inclusion
This article discusses the importance of DEI in rare disease clinical trials and shares actionable points for a more inclusive approach.
Expert Q&A: The impact of the clinical trial liaison function
The impact of the clinical trial liaison function (CTL) in developing and delivering optimal clinical trials.